DR. SATHISH KUMAR MUNGAMURI

Scientist - E, 
Division of Food Safety


Email:  mungamurisk@gmail.com
Contact:  +91-40-27197281

Brief Profile

Dr. Sathish Kumar Mungamuri obtained his Ph.D. from the Indian Institute of Science and subsequently received post-doctoral training at the Department of Oncological Sciences at Icahn School of Medicine, Mount Sinai School of Medicine, New York, USA. Dr. Sathish was educated in molecular cancer therapeutics and is a specialist in cancer cell signaling and epigenetics. He is a recipient of the Young Scientists Cancer Research Award from Tisch Cancer Institute, New York, and Forchheimer Foundation scholarship during his stay in New York. He also served as a co-investigator for the Breast Cancer research foundation-funded project “Novel Breast Cancer Markers and Mechanisms.” He also served as a co-investigator of the NIH P01 project entitled “p53 effectors and regulators”. He was awarded the Ramanujan Fellowship from Science and Engineering Research Board, Department of Science and Technology, Govt. of India in 2019. In September 2019, Dr. Sathish joined as a Scientist-E in the Division of Food Safety, NIN. He also serves as a member of the Research Integrity Committee, NIN, and a member of the Academic Committee for M.Sc. Applied Nutrition and M.Sc. Sports Nutrition programs at ICMR-NIN. Currently, his lab's primary research theme is to elucidate the Indian food-borne carcinogenesis mechanisms and characterize the role of nutrients in cancer prevention and support.

Total Research Publications: 21 (In the last 10 years: 19)
  1. Mungamuri SK*, Sinha SN and Javvadi Y. Understanding the Alterations in Lipid Metabolism in NAFLD Progression: Current Trends and Future Directions. Critical Reviews in Oncogenesis. Accepted for Publication. *Corresponding Author. 
  2. Nanchari, SR*, Mungamuri, SK* and Venkatesan, V. Targeted therapy for triple-negative breast cancer: current trends and future directions. Journal of Cell and Tissue Research. Vol. 20(2): 6983-6992 (2020). *Equal First Author. 
  3. Mungamuri SK* and Vijayasarathy K (2020). The Role of Gut Microbiome in the Non-Alcoholic Fatty-Liver Disease Progression. Critical Reviews in Oncogenesis. 2020 Aug 21. 25 (1): 57 - 70. DOI: 10.1615/CritRevOncog.2020035667. *Corresponding Author.
  4. Mungamuri SK* and Mavuduru VA (2020). Role of epigenetic alterations in aflatoxin-induced hepatocellular carcinoma. Liver Cancer International. 2020 July 20. 1-10. DOI: http://dx.DOI.org/10.1002/lci2.20 *Corresponding Author.
  5. Nishad R, Mukhi D, Tahaseen SV, Mungamuri SK, Pasupulati AK. Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy. Journal of Biological Chemistry. 2019 Nov 1;294(44):16109-16122. DOI: 10.1074/jbc.RA119.008966. Epub 2019 Sep 11. PubMed PMID: 31511328; PubMed Central PMCID: PMC6827306.
  6. Raju GS, Dariya B, Mungamuri SK, Chalikonda G, Kang S-M, Khan IN, Sushma PN, Nagaraju GP, Pavitra E, Hana Y-K (2019). Nanomaterials multifunctional behavior for enlighten cancer therapeutics. Seminars in Cancer Biology. 2019 Aug 13. pii: S1044-579X(19)30190-7. DOI: 10.1016/j.semcancer.2019.08.013.
  7. Nakuluri K, Mukhi D, Mungamuri SK, Pasupulati AK. Stabilization of hypoxia-inducible factor 1α by cobalt chloride impairs podocyte morphology and slit-diaphragm function. Journal of Cellular Biochemistry. 2018Nov 1. DOI: 10.1002/jcb.28041. PubMed PMID: 30387200. 
  8. Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, Moran T, Flavell R, Aaronson S, Hu HM, Arase H, Ramanathan S, Flores R, Pan PY, Chen SH. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. Journal of Clinical Investigation. 2018Dec 3;128(12):5647-5662. DOI: 10.1172/JCI97570. Epub 2018 Oct 22. PubMed PMID: 30352428; PubMed Central PMCID: PMC6264729. 
  9. Nakuluri K, Mukhi D, Nishad R, Saleem MA, Mungamuri SK*, Menon RK, Pasupulati AK*. Hypoxia induces ZEB2 in podocytes: Implications in the pathogenesis of proteinuria. Journal of Cellular Physiology. 2019May;234(5):6503-6518. DOI: 10.1002/jcp.27387. Epub 2018 Sep 21. PubMed PMID: 30238984. *Equal Corresponding Authors. 
  10. Van der Touw W, Kang K, Luan Y, Ma G, Mai S, Qin L, Bian G, Zhang R, Mungamuri SK, Hu HM, Zhang CC, Aaronson SA, Feldmann M, Yang WC, Chen SH, Pan PY. Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. Journal of Immunology. 2018Sep 15;201(6):1727-1734. DOI: 10.4049/jimmunol.1701450. Epub 2018 Aug 1. PubMed PMID: 30068593; PubMed Central PMCID: PMC6379207.
  11. Guernet A, Mungamuri SK, Cartier D, Sachidanandam R, Jayaprakash A, Adriouch S, Vezain M, Charbonnier F, Rohkin G, Coutant S, Yao S, Ainani H, Alexandre D, Tournier I, Boyer O, Aaronson SA, Anouar Y, Grumolato L. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Molecular Cell. 2016 Aug 4;63(3):526-38. DOI: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21. PubMed PMID: 27453044; PubMed Central PMCID: PMC5537739.
  12. Troilo A, Benson EK, Esposito D, Garibsingh RA, Reddy EP, Mungamuri SK, Aaronson SA. Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations.  2016May 17;7(20):28765-82. DOI: 10.18632/oncotarget.9117. PubMed PMID: 27144834; PubMed Central PMCID: PMC5045355.
  13. Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation. Cell Reports. 2016Mar 22;14(11):2528-37. DOI: 10.1016/j.celrep.2016.02.049. Epub 2016 Mar 10. PubMed PMID: 26971997; PubMed Central PMCID: PMC4884055.
  14. Mungamuri SK, Wang S, Manfredi JJ, Gu W, Aaronson SA. Ash2L enables p53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters.  2015May 7;34(19):2461-70. DOI: 10.1038/onc.2014.198. Epub 2014 Jul 14. PubMed PMID: 25023704; PubMed Central PMCID: PMC4295002.
  15. Zhang X, Campreciós G, Rimmelé P, Liang R, Yalcin S, Mungamuri SK, Barminko J, D'Escamard V, Baron MH, Brugnara C, Papatsenko D, Rivella S, Ghaffari S. FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. American Journal of Hematology. 2014Oct;89(10):954-63. DOI: 10.1002/ajh.23786. Epub 2014 Jul 22. PubMed PMID: 24966026; PubMed Central PMCID: PMC4201594.
  16. Mungamuri SK, Murk W, Grumolato L, Bernstein E, Aaronson SA. Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers. Cell Reports. 2013Oct 31;5(2):302-13. DOI: 10.1016/j.celrep.2013.09.009. Epub 2013 Oct 10. PubMed PMID: 24120871; PubMed Central PMCID: PMC3905738.
  17. Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, Aaronson SA. p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes.  2014Jul 24;33(30):3959-69. DOI: 10.1038/onc.2013.378. Epub 2013 Oct 7. PubMed PMID: 24096481; PubMed Central PMCID: PMC4067464.
  18. Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, Manfredi JJ. The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes and Development. 2013Sep 1;27(17):1868-85. DOI:10.1101/gad.224386.113. PubMed PMID: 24013501; PubMed Central PMCID: PMC3778241.
  19. Grumolato L, Liu G, Haremaki T, Mungamuri SK, Mong P, Akiri G, Lopez-Bergami P, Arita A, Anouar Y, Mlodzik M, Ronai ZA, Brody J, Weinstein DC, Aaronson SA. β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS Genetics. 2013;9(8):e1003603. DOI: 10.1371/journal.pgen.1003603. Epub 2013 Aug 15. PubMed PMID: 23966864; PubMed Central PMCID: PMC3744423.
  20. Das S, Sarrou E, Podgrabinska S, Cassella M, Mungamuri SK, Feirt N, Gordon R, Nagi CS, Wang Y, Entenberg D, Condeelis J, Skobe M. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. Journal of Experimental Medicine. 2013Jul 29;210(8):1509-28. DOI: 10.1084/jem.20111627. Epub 2013 Jul 22. PubMed PMID: 23878309; PubMed Central PMCID: PMC3727324.
  21. Mungamuri SK, Benson EK, Wang S, Gu W, Lee SW, Aaronson SA. p53-mediated heterochromatin reorganization regulates its cell fate decisions. Nature Structural and Molecular Biology. 2012Apr 1;19(5):478-84, S1. DOI: 10.1038/nsmb.2271. PubMed PMID: 22466965; PubMed Central PMCID: PMC4009975.
  22. Muñoz-Fontela C, Pazos M, Delgado I, Murk W, Mungamuri SK, Lee SW, García-Sastre A, Moran TM, Aaronson SA. p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. Journal of Immunology. 2011 Dec 15;187(12):6428-36. DOI: 10.4049/jimmunol.1101459. Epub 2011 Nov 21. PubMed PMID: 22105999; PubMed Central PMCID: PMC3275346.
  23. Zhang X, Yalcin S, Lee DF, Yeh TY, Lee SM, Su J, Mungamuri SK, Rimmelé P, Kennedy M, Sellers R, Landthaler M, Tuschl T, Chi NW, Lemischka I, Keller G, Ghaffari S. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nature Cell Biology. 2011Jul 31;13(9):1092-9. DOI: 10.1038/ncb2293. PubMed PMID: 21804543; PubMed Central PMCID: PMC4053529.
  24. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R, Ghaffari S. ROS-mediated amplification of AKT/mTOR signaling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. EMBO Journal. 2010Dec 15;29(24):4118-31. DOI: 10.1038/emboj.2010.292. Epub 2010 Nov 26. PubMed PMID: 21113129; PubMed Central PMCID: PMC3018793.
  25. Mungamuri SK, Yang X, Thor AD, Somasundaram K. (2006). Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.Cancer Research. May 1; 66(9):4715-24. PMID: 16651424.
  26. Somasundaram K, Mungamuri SK, Wajapeyee N. (2002). DNA Microarray Technology and its Applications in Cancer Biology. Applied Genomics and Proteomics. 1(4) 209 - 218.
Total Number of Book chapters: 3 (In the last 10 years: 3)

  1. Mungamuri SK* and Javvadi Y. (October 2020). “Role of Dietary Supplementation of Natural products in the Prevention and Treatment of Liver Diseases” in a book entitled “Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers” by Springer Publications. Hardcover ISBN: 978-3-030-48404-0; eBook ISBN: 978-3-030-48405-7. *Corresponding Author
  2. Mungamuri SK, Pasupulati AK and Mavuduru VA. (November 2019). “Immunotherapy for Diabetogenic Pancreatitis and Pancreatic Cancer: An Update” in book entitled “Exploring Pancreatic Metabolism and Malignancy” by Springer Publications. Paperback ISBN: 978-981-32-9392-2; eBook ISBN: 978-981-32-9393-9.
  3. Mungamuri SK. (August 2019). “Targeting the Epigenome as a Therapeutic Strategy for Pancreatic Tumors - Non-coding RNAs and Chromatin Remodelers” in book entitled “Theranostic Approach for Pancreatic Cancer” by Elsevier publications. Paperback ISBN: 9780128194577. eBook ISBN: 978-981-32-9393-9.
  4. Mungamuri SK. (March 2019). “Targeting the Epigenome as a Therapeutic Strategy for Pancreatic Tumors - DNA and histone modifying enzymes” in book entitled “Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy” by Elsevier publications. eBook ISBN: 9780128176627; Hardcover ISBN: 9780128176610.
Awards and Honors

  1. Ramanujan Fellowship (2019) - Science and Engineering Research Board, Department of Science and technology, Govt. of India.
  2. Young Scientist Cancer Research Award (2016 - 2017), Tisch Cancer Institute - Icahn School of Medicine at Mount Sinai
  3. Leo and Julia Forchheimer Foundation Fellowship (2015 - 2017), Mount Sinai School of Medicine.
  4. Travel award from American Society of Hematology for attending 50th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Francisco, CA. Dec 2008.
  5. Qualified for Joint All India All India Council of Scientific and Industrial Research-University Grants Commission Senior Research Fellowship, INDIA (SRF), Jul 2003.
  6. Qualified Joint All India Council of Scientific and Industrial Research-University Grants Commission Junior Research Fellowship (JRF) and Eligibility for Lectureship - National Eligibility Test (NET). Jul 2001.
  7. Qualified National Level Test for Ph.D. fellowship at Indian Institute of Science, Bangalore, India, May 2001.
  8. Qualified joint CSIR-UGC National Eligibility Test (NET) for Lectureship, Dec 2000.
  9. Secured 11th Rank and Qualified in National level entrance test, for Master’s Program in Biochemistry, at Osmania University, Hyderabad. INDIA, Jun 1999.
  10. Qualified All India National level “Graduate Aptitude test for Engineering” GATE in the year 2001, with a Percentile score of 94.20.
  11. 1st Ranker of the Osmania University, Hyderabad, INDIA by securing highest marks in master’s degree (M.Sc. Biochemistry).
  12. Received “Miss Jayashree Kannan Memorial Gold Medal” for securing highest marks in M.Sc. Final Biochemistry, 2001.
  13. Selected as a student in National level exam for Participation in summer training program of the “Centre for Cellular and Molecular Biology” CCMB, during summer of 2000.